Home - Gastroenterology Advisor
WEBFDA Alert: Gastroenterology Drug Approvals and New Indications. The FDA approved a biosimilar for inflammatory bowel diseases and issued several new indications for nonerosive GERD, UC, and PFIC.
Clinician Insights on How to Manage Semaglutide-Induced …
WEBSep 8, 2023 · Patients who receive treatment with a glucagon-like peptide-1 (GLP-1) receptor agonist, such as semaglutide, may experience delayed gastric emptying due to the drug’s mechanism of action (MOA). 1 Symptoms may include nausea, vomiting, heartburn, pain, or bloating. 2 However, the symptoms of delayed gastric emptying resulting from GLP-1 receptor agonists may be similar to symptoms of ...
What We Know About Semaglutide Adverse Events and …
WEBSep 1, 2023 · What Are Other Causes of Gastroparesis? Diabetes is the most common underlying cause of gastroparesis and can damage the vagus nerve, leading to impaired muscular function in the stomach and small intestine. 3 Studies show that the 10-year cumulative incidence of diabetic gastroparesis is estimated to be 5.2% among patients with type 1 diabetes and 1% in patients with type 2 diabetes. 4
New Oral Tablet Prep for Colonoscopy: The Important Details
WEBFeb 8, 2021 · Importance of Adequate Bowel Prep. From the perspective of the gastroenterologist, adequate bowel prep is crucial in screening colonoscopy, for which it is used to detect cancerous and precancerous lesions, and in diagnostic colonoscopy, such as that performed because of bleeding or diarrhea. Up to 25% of patients undergoing colonoscopy may ...
Assessment of Antispasmodics Available in North America for the ...
WEBOct 15, 2021 · Data on the use of antispasmodics available in North America for the treatment of chronic abdominal pain in patients with disorders of gut-brain interaction (DGBI) vary dramatically in safety and efficacy, according to a literature review published in The American Journal of Gastroenterology.Overall, data supporting the use of antispasmodics in this patient population are lacking.
Tradipitant Relieves Nausea, Other Gastroparesis Symptoms
WEBOct 27, 2022 · Tradipitant is efficacious for relieving nausea and other gastroparesis symptoms. Tradipitant significantly improved nausea and other symptoms in patients with idiopathic and diabetic gastroparesis compared with placebo, according to study results presented at the American College of Gastroenterology (ACG) 2022 Annual Meeting, held from October ...
Gastroparesis Awareness Month: Updated Guidelines to Treat …
WEBAug 19, 2022 · The American College of Gastroenterology (ACG) released updated clinical guidelines on managing gastroparesis (GP). The new recommendations were published in The American Journal of Gastroenterology.. GP is characterized by delayed gastric emptying (GE) of solid food in the absence of mechanical obstruction.
2021 American College of Gastroenterology Guidelines: Upper ...
WEBJun 2, 2021 · The American College of Gastroenterology (ACG) released clinical guidelines on upper gastrointestinal (GI) and ulcer bleeding using an evidence-based approach, which was recently published in The American Journal of Gastroenterology.. The researchers used the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology to develop 16 clinical recommendations for the ...
Novel Drug Tradipitant Effective, Safe for Treatment of Nausea in ...
WEBOct 29, 2021 · Tradipitant appears to be an effective and safe treatment option for gastroparesis symptoms, according to research presented at the American College of Gastroenterology (ACG) 2021 Annual Meeting, held from October 22 to 27, 2021, in Las Vegas, Nevada and virtually.
Controversies in the Diagnosis and Treatment of Gastroparesis
WEBIn an editorial published by the American Journal of Gastroenterology, authors Brian E. Lacy, MD, PhD and David J. Cangemi, MD addressed common misconceptions regarding the diagnosis and treatment of gastroparesis (GP).The prevalence, etiology, and pathogenesis of GP were described, along with diagnostic techniques and prognosis.